HOPE Biobank for bone marrow failure patients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study collects blood samples from patients with aplastic anemia, sickle cell disease, thalassemia, or other bone marrow failure conditions who are receiving a stem cell transplant or gene therapy. The samples will be stored and used for future research to better understand and treat these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have aplastic anemia, sickle cell disease, thalassemia, or another type of bone marrow failure that is not cancer.
- You are going to have a stem cell transplant or gene therapy for your condition.
- You weigh at least 22 pounds (10 kilograms) at the time you join the study.
- You agree to let the research team link your study data with your medical records from the transplant registry.
- If you are a related donor for an eligible patient, you can also join this study. The patient can still join even if you decide not to.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
This trial tests a way to lower the risk of graft-versus-host disease (GVHD), a common complication after a bone marrow transplant, by removing certain immune cells from the donor's stem cells before giving them to the patient. It is for young children with non-cancerous blood or immune diseases who need a transplant.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial is a registry that follows children and young adults up to age 26 who are having a bone marrow transplant, to better understand complications related to blood vessel and organ injury. It may help future patients by improving how doctors predict and prevent these problems.
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
Hear when a new Hemoglobinopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.